AlphaRx Inc. has completed the formulation development of a novel antibiotic formulation using its patent pending solid lipid nanoparticle delivery platform.
The new product is under the trade name Vansolin; the active ingredient is Vancomycin, a very powerful antibiotic being used mainly in hospitals around the world to treat life-threatening infectious disease such as hospital acquired pneumonia, ventilator associated pneumonia and severe sepsis. Vansolin is the company's 4th product employing proprietary nanotechnology intended to increase the efficacy of existing drug compound while reducing its side effects.
The company believes that encapsulating Vancomycin into nanoparticles may increase its efficacy. According to published research papers, in vitro the uptake of Vancomycin nanoparticles by white blood cells is 20 times more than free drug. The Company hopes that these white blood cells will absorb Vansolin nanoparticles after IV infusion and carry them to the site of inflammation, thereby increasing the local concentration of Vancomycin and ultimately increasing its bactericidal activity.
The company had completed formulation development of Zysolin, a novel antibiotic nanoparticles intended to treat hospital acquired pneumonia and outlined its clinical development strategy. Vansolin will be developed using the same strategy. The company expects to advance Vansolin into clinical phase by end of 2006, stated a release.